This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.
Researchers compared high-dose versus standard-dose influenza vaccines in adults aged 65 to 79 years to determine whether enhanced immunogenicity translates into reduced severe clinical outcomes, including...
A new phase 3 trial evaluated whether a quadrivalent modified mRNA influenza vaccine could match or exceed the efficacy of a licensed inactivated influenza vaccine in adults aged 18–64 years during the...
New studies highlight that while persistent SARS-CoV-2 infections can evolve rapidly within individuals, they rarely spread onward. Meanwhile, the 2024–2025 COVID-19 vaccine reduced mortality by 64% among...
In this roundup, experts outline diverging pediatric COVID vaccine recommendations, midlife peaks in long COVID risk, new findings on abnormal uterine bleeding and cycle-related symptoms in long COVID, and...
From respiratory syncytial virus monoclonal antibody approvals to thimerosal-free vaccine preferences, ACIP’s latest guidance has important implications for your practice.
A randomized trial comparing influenza vaccines over two seasons found that recombinant vaccines showed stronger immune responses to A/H3N2 strains compared with egg-based and cell culture-based vaccines.
...
The Advisory Committee on Immunization Practices released its updated annual immunization schedule for 2024 that includes new sections on respiratory syncytial virus (RSV), and the mpox (monkeypox) and...
